1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) pipeline Target constitutes close to 15 molecules. The latest report Glial Cell Line Derived Neurotrophic Factor - Pipeline Review, H2 2020, outlays comprehensive information on the Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Glial -derived neurotrophic factor is a member of the cysteine-knot superfamily of growth factors. It promotes the survival and differentiation of dopaminergic neurons and was able to prevent apoptosis of motor neurons. The mature form of the protein is a ligand for the product of the RET (rearranged during transfection) protooncogene. The molecules developed by companies in Phase II and Preclinical stages are 3 and 10 respectively. Similarly, the universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Ophthalmology and Cardiovascular which include indications Parkinson's Disease, Amyotrophic Lateral Sclerosis, Glaucoma, Ischemic Stroke, Keratoconjunctivitis Sicca (Dry Eye), Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy), Neurodegenerative Diseases, Neuropathic Pain (Neuralgia), Peripheral Nerve Injury, Radiculopathy, Retinal Degeneration and Retinitis Pigmentosa (Retinitis).
Furthermore, this report also reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)
- The report reviews Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Introduction
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Therapeutics Development
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Therapeutics Assessment
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Companies Involved in Therapeutics Development
AMT-090 - Drug Profile
Drugs for Neurodegenerative Diseases - Drug Profile
Fusion Protein to Activate GDNF for Brain Ischemia - Drug Profile
Gene Therapy to Activate GDNF for Amyotrophic Lateral Sclerosis and Retinitis Pigmentosa - Drug Profile
Gene Therapy to Activate GDNF for Parkinson's Disease - Drug Profile
GSK-812 - Drug Profile
KLS-2031 - Drug Profile
LAUR-101 - Drug Profile
LAUR-301 - Drug Profile
NRO-1 - Drug Profile
Protein to Activate GDNF for Parkinson's Disease - Drug Profile
smilagenin - Drug Profile
ST-502 - Drug Profile
Stem Cell Therapy to Activate BDNF, GDNF, IGF1 and VEGF for Peripheral Nerve Injury and Neuropathic Pain - Drug Profile
TW-002 - Drug Profile
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Product Development Milestones
Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Biogen Inc
- Copernicus Therapeutics Inc
- Eli Lilly and Co
- GlaxoSmithKline Plc
- Junaxo Inc
- Kai Nuo Bio Sci Co Ltd
- Kolon Life Science Inc
- Lauren Sciences LLC
- Neuroptika Inc
- Stem Cell Medicine Ltd
- Treeway BV
- UniQure NV